

Univariate analysis of receipt of RT in the last 30 days of life (RT30)			
Characteristic	No	% treated with RT30	P
Entire cohort	579	9.2	
Year of death			
2007	106	3.8	.192
2008	194	10.3	
2009	214	10.7	
2010	46	13	
2011	11	0	
ECOG performance status <sup>1</sup>			
0	75	1.3	<.001
1	160	1.9	
2	180	4.4	
3	144	22.2	
4	19	47.4	
Family <sup>1</sup>			
Single	162	11.1	.743
Married	320	9.1	
Partner	45	11.1	
Age at RT (years)			
< 60	96	6.3	.280
≥ 60	483	9.7	
Age at RT (years)			
< 65	188	6.4	.154
65-69	91	6.6	
70-74	85	15.3	
75-79	112	10.7	
≥ 80	103	9.7	
Gender			
Male	356	10.7	.112
Female	222	6.8	
Primary tumor site			
Prostate	145	7.6	.025
Breast	67	0	
Lung (small cell)	31	16.1	
Lung (non-small cell)	105	17.1	
Colorectal	37	8.1	
Pancreas	9	11.1	

Bladder	32	12.5	
Lymphoma	7	14.3	
Multiple Myeloma	24	4.2	
Others	122	7.4	
Dichotomized site2			
Bladder + Lung	164	16.5	<.001
Others	415	6.3	
Analgetics1			
No opioids	197	4.6	.001
Opioids	314	13.7	
Analgetics1			
No opioids	197	4.6	.001
Opioids per os/transdermal	290	12.8	
Opioids via pump	24	25.0	
Incomplete RT			
No	554	7.9	<.001
Yes	25	36.0	
Total no of TV in RT course			
1	389	9.8	.755
2	155	7.7	
3	35	8.6	
No of RT fractions			
1-4	114	16.7	<.001
5-9	140	15.7	
10	210	3.8	
11-15	90	3.3	
16-20	9	11.1	
>20	16	0	
Dose per fraction [Gy]			
2 or less	18	5.6	.001
2.1 – 2.9	42	7.1	
3	262	4.2	
3.1 – 3.9	16	0	
4	125	16.8	
4.1 – 5	26	11.5	
More than 5	90	15.6	
Previous RT1			

No	328	9.5	.950
One course	186	8.6	
More than one course	65	9.2	
Reirradiation to same TV1			
No	488	9.8	.318
Yes	82	4.9	
Minor overlap	7	14.3	
Selected target types			
Bone metastases	314	8.9	.808
Brain metastases	68	7.4	
Lymph node metastases	34	8.8	
More than 1 cancer diagnosis <sup>1</sup>			
No	506	8.5	.116
Yes	70	14.3	
Albumin before RT1			
Low	258	4.3	.116
Normal	96	14.3	
LDH before RT1			
High	148	10.8	.242
Normal	132	6.8	
Hemoglobin before RT1			
Low	363	12.9	.001
Normal	169	3.6	
ALP before RT1			
High	171	11.7	.372
Normal	171	8.8	
Leukocyte count before RT1			
Low	16	12.5	<.001
Normal	374	6.7	
High with steroids	69	24.6	
High without steroids	41	12.2	
Creatinine before RT1			
Low	73	24.7	<.001
Normal	321	6.5	
High	95	9.5	

CRP before RT1			
Normal	164	3.0	<.001
Elevated < 30 mg/l	146	6.8	
30-60	93	20.4	
60-90	34	14.7	
> 90	62	21.0	
Thrombocyte count before RT1			
Low	37	16.2	.187
Normal	269	7.8	
High	141	11.3	
Oxygen treatment1			
No	566	8.5	<.001
Yes	8	62.5	
Known brain metastases1			
No	483	9.3	.850
Yes	92	8.7	
Known liver metastases1			
No	459	7.8	.023
Yes	116	14.7	
Known lung metastases1			
No	451	9.3	.880
Yes	124	8.9	
Known adrenal gland met.1			
No	518	8.7	.185
Yes	57	14.0	
Known bone metastases1			
No	194	8.8	.788
Yes	381	9.4	
Progressive disease outside TV1			
No	207	5.3	.011
Yes	345	11.9	
SVCC1			
No	564	8.7	.056
Yes	12	24.0	

MSCC1			
No	512	9.0	.498
Yes	60	11.7	
Pleural effusion1			
No	515	7.2	<.001
Yes	61	26.2	
Hypercalcemia1			
No	378	9.5	.016
Yes	24	25.0	
Charlson comorbidity index1,3			
0	37	2.7	.010
1-2	255	6.7	
3-4	187	13.9	
5 and above	46	17.4	
Diabetes mellitus1			
No	476	9.7	.984
Yes	73	9.6	
COPD1			
No	488	9.2	.332
Yes	61	13.1	
Serious heart disease1			
No	316	8.2	.234
Infarction or revascularization	69	7.2	
Pacemaker or arrhythmia only	44	11.4	
Other	119	14.3	
Smoking history1			
None	210	7.6	.223
Active smoker	134	9.7	
Quitted before RT	144	13.2	
No of prescriptions drugs1			
0	10	0	.024
1-3	83	2.4	
4-9	245	12.7	
10 and above	144	13.9	
Steroids at start of RT1			

No	249	6.4	.003
Yes	252	14.7	
Anticoagulation <sup>1</sup>			
No	300	8.7	.069
Yes	195	13.8	
Blood transfusion <sup>1</sup>			
No	520	8.5	.012
During or within 2 weeks before RT	39	20.5	
Treated by palliative team <sup>1</sup>			
No	382	8.6	.333
Yes	140	11.4	
Systemic cancer treatment <sup>1</sup>			
No	256	10.9	.755
Within 4 weeks before RT	118	8.5	
Within 3 months before RT	69	7.2	
Earlier	79	8.9	

RT: Radiotherapy, TV: Target volume, LDH: lactate dehydrogenase, ALP: alkaline phosphatase, CRP: c-reactive protein, SVCC: superior vena cava compression, MSCC: metastatic spinal cord compression, COPD: chronic obstructive pulmonary disease

<sup>1</sup>missing information in some cases

<sup>2</sup>due to small number of cases pancreas cancer and lymphoma was not added to lung and bladder cancer

<sup>3</sup>excluding actual cancer diagnosis

Other factors that did not predict for RT30: time from first cancer diagnosis to palliative RT, time from first metastasis (if any) to palliative RT, target volume localization (e.g. brain, lung, spine etc.)